Facundo Damian Batista is a professor of biology at MIT, the chief editor of the EMBO Journal,. and an associate director, scientific director, and principal investigator at the Ragon Institute of Mass General, MIT, and Harvard. An expert in B cells and antibodies, he studies their fundamental biology and their applications to immunology and vaccine development.
Raised in Argentina, Batista developed a passion for molecular biology at the University of Buenos Aires. He earned his Master of Science degree in biology in 1993 and a Ph.D. in biology in 1995 from the International School of Advanced Studies in Trieste.
From 1996 to 2002, Batista trained with Michael Neuberger as an EMBO Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge. There, Batista and Neuberger researched the relationship between B cell responses and antigen affinity, publishing their findings in Immunity[1] and Nature.[2]
Joining the Ragon Institute in 2016, Batista established a research group that studies the mechanisms of B cell activation, which helps support vaccine development.[3] In 2017, Batista helped create a technique for developing human antibodies in the laboratory.[4] The method helps accelerate the process of developing therapeutic antibodies.[5] It also supports vaccine development, allowing researchers to test them in artificial immune systems[6] before clinical trials.
Batista’s work at the Ragon Institute developed technical innovations for the genetic engineering of mice[7] with humanized B cell receptors. The resulting animal models enable researchers to test vaccines.. The technique also led to a new HIV vaccine design strategy[8] and could support the development of vaccines against the flu, dengue, malaria and hepatitis C.[9] Batista and the team published their findings from this line of research in The EMBO Journal[10] and Science.[11]
References
edit- ^ Batista, Facundo (June 1, 1998). "Affinity Dependence of the B Cell Response to Antigen: A Threshold, a Ceiling, and the Importance of Off-Rate". Immunity. 8 (6): 751–759. doi:10.1016/s1074-7613(00)80580-4. PMID 9655489.
- ^ Batista, Facundo D.; Iber, Dagmar; Neuberger, Michael S. (May 2001). "B cells acquire antigen from target cells after synapse formation". Nature. 411 (6836): 489–494. doi:10.1038/35078099. ISSN 1476-4687. PMID 11373683.
- ^ "Germline-Targeting Approach Defined for HIV Vaccine". www.precisionvaccinations.com. Retrieved 2024-08-07.
- ^ "Technique Rapidly Generates Monoclonal Antibodies In Vitro". The Scientist Magazine®. Retrieved 2024-08-07.
- ^ "Technique Rapidly Generates Monoclonal Antibodies In Vitro". The Scientist Magazine®. Retrieved 2024-08-07.
- ^ "Test-tube Immune Systems Can Speed Vaccine Development". Voice of America. 2017-07-24. Retrieved 2024-08-07.
- ^ "One-step method developed to generate mice for vaccine research". Drug Target Review. Retrieved 2024-08-07.
- ^ "Germline-Targeting Approach Defined for HIV Vaccine". www.precisionvaccinations.com. Retrieved 2024-08-07.
- ^ "Germline-Targeting Approach Defined for HIV Vaccine". www.precisionvaccinations.com. Retrieved 2024-08-07.
- ^ Wang, Xuesong; Ray, Rashmi; Kratochvil, Sven; Melzi, Eleonora; Lin, Ying-Cing; Giguere, Sophie; Xu, Liling; Warner, John; Cheon, Diane; Liguori, Alessia; Groschel, Bettina; Phelps, Nicole; Adachi, Yumiko; Tingle, Ryan; Wu, Lin (2021-01-15). "Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors". The EMBO Journal. 40 (2): e105926. doi:10.15252/embj.2020105926. ISSN 0261-4189. PMC 7809789. PMID 33258500.
- ^ Giguère, Sophie; Wang, Xuesong; Huber, Sabrina; Xu, Liling; Warner, John; Weldon, Stephanie R.; Hu, Jennifer; Phan, Quynh Anh; Tumang, Katie; Prum, Thavaleak; Ma, Duanduan; Kirsch, Kathrin H.; Nair, Usha; Dedon, Peter; Batista, Facundo D. (2024-01-12). "Antibody production relies on the tRNA inosine wobble modification to meet biased codon demand". Science. 383 (6679): 205–211. Bibcode:2024Sci...383..205G. doi:10.1126/science.adi1763. ISSN 0036-8075. PMC 10954030. PMID 38207021.
This article needs additional or more specific categories. (August 2024) |